Overview

A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma

Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
To observe the safety, tolerability and clinical effects of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma.
Phase:
Phase 4
Details
Lead Sponsor:
Mingzhi Zhang
Treatments:
Etoposide